Current Issue Volume 7 | Issue 1 | TEXILA INTERNATIONAL JOURNAL OF CLINICAL RESEARCH

Home

Table of Contents - Issue

August 2026

Volume 7 | Issue 1

ISSUE DOI: 10.21522/TIJCR.2014.07.01

[Download Full Issue]

Recent articles

Perceived Susceptibility of Glaucoma among Healthcare Workers in a Tertiary Hospital in Ogun State, Nigeria

Author: Timothy Olatunji OLADOSU

DOI: 10.21522/TIJCR.2014.07.01.Art001

[ABSTRACT] [Full-Text PDF] [REFERENCES]

Perceived Susceptibility of Glaucoma among Healthcare Workers in a Tertiary Hospital in Ogun State, Nigeria

Abstract:

Glaucoma is a leading cause of irreversible blindness worldwide, particularly in sub-Saharan Africa, where late diagnosis and poor uptake of screening services remain major challenges. Perceived susceptibility plays a vital role in motivating preventive health behaviors, especially among healthcare workers who are expected to model healthy practices and promote eye health. This study assessed the perceived susceptibility to glaucoma among healthcare workers at Federal Medical Centre Abeokuta, Ogun State, Nigeria. An institutional-based cross-sectional survey was conducted among 271 healthcare workers selected using a multistage sampling technique. Data were collected using a structured, self-administered questionnaire adapted from validated glaucoma perception instruments. Descriptive statistics summarized the data, while Chi-square tests examined associations between socio-demographic characteristics and perceived susceptibility to glaucoma at a significance level of p < 0.05. The findings revealed that 66.4% of respondents had never undergone an eye examination, and only 16.2% had previously been screened for glaucoma. Although respondents demonstrated moderate awareness of glaucoma risk factors, with diabetes (Mean = 3.93), cataracts (Mean = 3.82), and previous eye surgery (Mean = 3.82) identified as major risks, 67.5% did not perceive themselves to be at risk of developing glaucoma. Low perceived susceptibility was mainly attributed to the absence of a family history of glaucoma and the lack of perceived eye problems. No significant association was found between socio-demographic characteristics and perceived susceptibility (p > 0.05). Despite moderate awareness of glaucoma risk factors, healthcare workers demonstrated poor perceived susceptibility and low uptake of glaucoma screening. Strengthening institutional eye health education and implementing routine workplace glaucoma screening programmes may improve risk perception, encourage preventive practices, and promote early detection.

Perceived Susceptibility of Glaucoma among Healthcare Workers in a Tertiary Hospital in Ogun State, Nigeria

References:

[1]. Kyari F, Entekume G, Rabiu M, Spry P, Wormald R, Nolan W, Murthy GVS, Gilbert C. A population-based survey of the prevalence and types of glaucoma in Nigeria: Results from the Nigeria National Blindness and Visual Impairment Survey. BMC Ophthalmol. 2015;15:176. https://doi.org/10.1186/s12886-015-0136-6

[2]. Yimam W, Anbesaw T, Seid M, Kumar P, Wolie H. Knowledge about glaucoma among adults in Africa: A systematic review. BMC Ophthalmol. 2024;24(1):69. https://doi.org/10.1186/s12886-024-03333-9

[3]. Bizuneh ZY, Tsega A, Addis Y, Admassu F. Awareness of glaucoma and associated factors among adults in Gish Abay Town, Northwest Ethiopia. Clin Optom. 2020;12:37-43. https://doi.org/10.2147/OPTO.S235538

[4]. Obasuyi OC, Yeye-Agba OO, Ofuadarho OJ. Factors limiting glaucoma care among glaucoma patients in Nigeria: A scoping review. PLoS Glob Public Health. 2024;4(1):e0002488. https://doi.org/10.1371/journal.pgph.0002488

[5]. Ndife TI. Knowledge, attitude, and self-care practice regarding glaucoma among hospital workers at a tertiary center in South-South Nigeria. BMC Ophthalmol. 2026;26(1):192. https://doi.org/10.1186/s12886-026-04832-7

[6]. Damji KF, Nazarali S, Giorgis A, Kiage D, Marco S, Philippin H, Daniel N, Amin S. STOP glaucoma in sub-Saharan Africa: Enhancing awareness, detection, management, and capacity for glaucoma care. Expert Rev Ophthalmol. 2017;12(3):197-206. https://doi.org/10.1080/17469899.2017.1295848

[7]. Oladosu TO, Awoseemo AB, Abiodun CS, Faronbi JO. Quality of life of patients with glaucoma in tertiary hospitals in Osun State, Nigeria. Nurs Scope. 2025;8(3):33-46. https://doi.org/10.59073/thenursingscope83/33-46

[8]. Mbadugha CA, Onakoya AO. The awareness, perceptions and experiences of primary open-angle glaucoma patients in Lagos, Nigeria. Sci Rep. 2014;4:7585. https://doi.org/10.1038/srep07585

[9]. Komolafe OO, Omolase CO, Bekibele CO, Ogunleye OA, Komolafe OA, Omotayo FO. Awareness and knowledge of glaucoma among workers in a Nigerian tertiary health care institution. Middle East Afr J Ophthalmol. 2013;20(2):163-7. https://doi.org/10.4103/0974-9233.110609

[10]. Osaguona VB, Edema OT. Awareness and knowledge of glaucoma among hospital workers at the University of Benin Teaching Hospital, Benin City. Sahel Med J. 2014;17(4):132-5. https://doi.org/10.4103/1118-8561.146816

[11]. Ejiakor IL, Onyia OE. Knowledge and myths about glaucoma among staff of a Nigerian tertiary hospital in South East Nigeria. Trans Ophthalmol Soc Niger. 2024;8(1):1-9.

[12]. Isawumi MA, Aina AS. Awareness and knowledge of glaucoma among workers in a missionary hospital in Nigeria. Res J Health Sci. 2024;12(3):180-8. https://doi.org/10.4314/rejhs.v12i3.2

[13]. Setia MS. Methodology series module 3: Cross-sectional studies. Indian J Dermatol. 2016;61(3):261-4. https://doi.org/10.4103/0019-5154.182410

[14]. Wang X, Cheng Z. Cross-sectional studies: Strengths, weaknesses, and recommendations. Chest. 2020;158(1 Suppl):S65-71. https://doi.org/10.1016/j.chest.2020.03.012

[15]. Yamane T. Statistics: An introductory analysis. 2nd ed. New York: Harper and Row; 1967.

[16]. De-Gaulle VF, Dako-Gyeke P. Awareness, knowledge and eye screening practices regarding glaucoma among adults in Ghana. Ghana Med J. 2016;50(3):145-52.

[17]. Sarimiye TF, Monye HI, Abiola VNI, Abo-Briggs JN, Ologundudu OO. An assessment of glaucoma awareness, uptake and satisfaction with a free targeted glaucoma screening programme in Ibadan, Nigeria. Trans Ophthalmol Soc Niger. 2022;7(1):22-30.

[18]. Okoye RS, Bell L, Papadopoulos I. Investigating the level of glaucoma awareness and perception of its risk factors in Anambra State, Nigeria. Public Health. 2018;160:100-7. https://doi.org/10.1016/j.puhe.2018.03.025

[19]. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-90. https://doi.org/10.1016/j.ophtha.2014.05.013

[20]. Alyafei A, Easton-Carr R. The Health Belief Model of Behavior Change. Treasure Island (FL): StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK606120/

Viewed	PDF
102	5

Bioanalytical Method Validation of Dasatinib in Human Plasma Using the LC-MS/MS Method

Author: Aruna Singam Reddy

DOI: 10.21522/TIJCR.2014.07.01.Art002

[ABSTRACT] [Full-Text PDF] [REFERENCES]

Bioanalytical Method Validation of Dasatinib in Human Plasma Using the LC-MS/MS Method

Abstract:

A sensitive and selective LC-MS/MS method for estimation of Dasatinib in K2EDTA human plasma was developed and validated. The concentration range was 1.0 ng/mL to 800.0 ng/mL. Sample preparation and analysis are carried out for Dasatinib as analyte using Dasatinib D₈ as internal standard. Analyte was separated by reverse phase chromatography using Thermo Hypurity C8 100*4.6 mm Column. Electro spray Ionization detections of Dasatinib, Dasatinib D₈ were carried out with multiple reaction monitoring of m/z 488.1/401.1, 496.1/406.1 respectively in positive ion mode [M+H]⁺ using a triple quadruple mass spectrometer. The retention time for Dasatinib and Dasatinib D₈ was 1.36 Minutes ± 30 seconds and 1.37 Minutes ± 30 seconds respectively with a total run time of 2.50 minutes. No interfering peaks or matrix effects were observed. This article provides the results of standard curves, quality control samples, recovery, and stability experiments. The LC-MS/MS method for the determination of Dasatinib in human plasma has specifications for sensitivity, reproducibility and accuracy.

Bioanalytical Method Validation of Dasatinib in Human Plasma Using the LC-MS/MS Method

References:

[1]. American Cancer Society. Key statistics for acute lymphocytic leukemia. 2024 Jan 17 [cited 2024 Nov 5]. Available from: https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/about/key-statistics.html

[2]. Apotex Corp. Apotex Corp. is the first generic manufacturer to launch dasatinib tablets in the United States. 2024 Sep 5 [cited 2024 Nov 5]. Available from: https://www.apotex.com/us/about-us/news/2024/09/05/apotex-corp.-is-the-first-generic-manufacturer-to-launch-dasatinib-tablets-in-the-united-states

[3]. Chokshi A, Gajjar A, Bhanushali P, Desai P. Quantification of antileukemic drug dasatinib in human plasma: application of a sensitive liquid chromatographic method. J Chem Metrol. 2021;15(2):152‑162. Available from: https://www.acgpubs.org/doc/20211226124933A5-64-JCM-2108-2174.pdf

[4]. Costa ER, Castro TN, Gonçalves‑de‑Albuquerque CF, Faria Neto HCC, Gonçalves JCS, Estrela RCE. Development and validation of liquid chromatography‑tandem mass spectrometry method to quantify dasatinib in plasma and its application to a pharmacokinetic study. Braz J Pharm Sci. 2023;59:e21415. doi:10.1590/s2175-97902023e21415.

[5]. DrugBank. Dasatinib (DB01254). 2024 [cited 2025 Sep 29]. Available from: https://go.drugbank.com/drugs/DB01254

[6]. Drugs.com. Availability of generic Sprycel. 2024 Nov 6 [cited 2024 Nov 6]. Available from: https://www.drugs.com/availability/generic-sprycel.html

[7]. Elsevier. Tyrosine kinase inhibitor. ScienceDirect. [cited 2024 Oct 27]. Available from: https://www.sciencedirect.com/topics/chemistry/tyrosine-kinase-inhibitor#chapters-articles

[8]. Furlong MT, Agrawal S, Hawthorne D, Lago M, Unger S, Krueger L, Stouffer B. A validated LC–MS/MS assay for the simultaneous determination of the anti‑leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2012;58:130‑5. doi:10.1016/j.jpba.2011.09.008.

[9]. Gora‑Tybor J, Robak T. A review of the management of chronic myeloid leukemia with dasatinib. Clin Med Ther. 2009;1. doi:10.4137/CMT.S1167.

[10]. International Council for Harmonisation. ICH guideline M10: bioanalytical method validation and study sample analysis. 2022 May 24 [cited 2024 Nov 20]. Available from: https://database.ich.org/sites/default/files/M10_Guideline_Step4_2022_0524.pdf

[11]. National Center for Biotechnology Information. PubChem Compound Summary for CID 3062316, Dasatinib. 2025 [cited 2025 Sep 29]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Dasatinib

[12]. National Cancer Institute. Cancer Stat Facts: Leukemia — Chronic Myeloid Leukemia (CML). [cited 2024 Nov 5]. Available from: https://seer.cancer.gov/statfacts/html/cmyl.html?form=MG0AV3

[13]. Phenomenex. Sample preparation reference manual and user’s guide. 2022 [cited 2024 Nov 20]. Available from: https://www.phenomenex.com/documents/sample-preparation-reference-manual--users-guide

[14]. Saraner N, Karagoz A, Guney B, Saglam O. Determination of dasatinib in human plasma using liquid chromatography‑tandem mass spectrometry. Int J Anal Bioanal Methods. 2019;1(1):002. Available from: https://vibgyorpublishers.org/content/ijabm/ijabm-1-002.pdf

[15]. Shodex HPLC Columns. Lesson 3: partition/adsorption chromatography. [cited 2024 Nov 20]. Available from: https://shodexhplc.com/lessons/lesson-3-partitionadsorption-chromatography/

[16]. Souza ID, Queiroz MEC. Innovations and strategies of sample preparation techniques to reduce matrix effects during LC–MS/MS bioanalysis. LCGC Suppl. 2021;39(s11):21‑3. Available from: https://www.chromatographyonline.com/view/innovations-and-strategies-of-sample-preparation-techniques-to-reduce-matrix-effects-during-lc-ms-ms-bioanalysis

[17]. Supriya V, Shakirunisa M, Santhi OK, Rani TS, Swathi CA, Padmalatha K. A review on bioanalytical method development and validation. Indo Am J Pharm Sci. 2021;8(5):210‑25. Available from: https://www.iajps.com/wp-content/uploads/2021/05/25.IAJPS25052021.pdf

[18]. U.S. Food and Drug Administration. Label for drug SPRYCEL® (dasatinib) (NDA 021986, Supplement 028). 2024 [cited 2024 Nov 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021986s028lbl.pdf

[19]. Winslow T. Acute lymphoblastic leukemia treatment. National Cancer Institute. 2024 [cited 2024 Nov 20]. Available from: https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq

[20]. Vardanyan R, Hruby V. Antineoplastic agents. In: Vardanyan R, Hruby V, editors. Synthesis of best‑seller drugs. Cambridge (MA): Academic Press; 2016. p. 495‑547. doi:10.1016/B978-0-12-411492-0.00028-6.

[21]. Zeng J, Cai H, Jiang Z, Wang Q, Zhu Y, Xu P, Zhao X. A validated UPLC–MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. J Pharm Anal. 2017;7(6):374‑80. doi:10.1016/j.jpha.2017.07.009.

Viewed	PDF
90	2

Epidemiological Study of Covid-19 (Coronavirus 2) in FCT, Abuja, Nigeria

Author: Christiana S. Kwabe

DOI: 10.21522/TIJCR.2014.07.01.Art003

[ABSTRACT] [Full-Text PDF] [REFERENCES]

Epidemiological Study of Covid-19 (Coronavirus 2) in FCT, Abuja, Nigeria

Abstract:

The current study evaluated the epidemiological characteristics and transmission features of COVID-19 in FCT, Abuja, Nigeria. A total of 385 participants from secondary and tertiary health facilities were enrolled for the study. It reported 23,239 confirmed cases with male preponderance (54.4%). The incidence was cumulated at a rate of 6.7 per 100,000, and the case fatality rate was 0.30%. Low vaccination rates were observed. Socio-demographic characteristics of the HCWs demonstrated that depression, anxiety, and financial concerns are all high in them. Again, health service delivery regarding immunization, family planning, and routine check-ups was badly affected due to the COVID-19 pandemic. However, it was recommended that strengthening the public health response through vaccination activities and providing support for HCWs would be some of the key things that could lessen the full impact brought about by COVID-19 within FCT.

Epidemiological Study of Covid-19 (Coronavirus 2) in FCT, Abuja, Nigeria

References:

[1]. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. Doi:10.1016/S0140-6736(20)30183-30183-5.

[2]. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Emergence, transmission, and characteristics of human Coronaviruses. 2020. https://doi.org/10.1016/j.jare.2020.03.005

[3]. Zhang T, Wu Q, Zhang Z. Probable Pangolin Origin of SARS-CoV-2 associated with the COVID-19 Outbreak. 2020.

[4]. Perlman S. Another decade, another coronavirus. N Engl J Med. 2020. Doi:0.1056/NEJMe2001126.

[5]. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767-72.

[6]. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814-20.

[7]. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-23. Doi: https://doi.org/10.1016/S0140-6736(20)30154-9

[8]. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020. Doi: 10.1056/NEJMoa2001191.

[9]. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020.

[10]. Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur Rev Med Pharmacol Sci. 2020;24(8):4539-47.

[11]. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. Doi: 10.1016/j.antiviral.2020.104787.

[12]. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment Coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/

[13]. Lai C, Hung Y, Wang C. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;2:10.

[14]. Zhang Y, Yu L, Tang L, Zhu M, Jin Y, Wang Z, et al. A promising anti-cytokine-storm targeted therapy for COVID-19: the artificial-liver blood-purification system. Engineering. 2020.

[15]. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020. DOI: 10.1056/NEJMc2001468.

[16]. Amzat J, Razum O. Toward sociology of health discourse in Africa. Cham, Switzerland: International Publication; 2018. https://link.springer.com/book/10.1007/978-3-319-61672-8?noAccess=true. Doi:10.1007/978-3-319-61672-8.

[17]. Nigeria Centre for Disease Control (NCDC). Covid-19 outbreak in Nigeria: situation report. 2020. https//ncdc.gov.ng/ng/diseases/sitreps.

[18]. The Irish Times. Coronavirus pandemic. 2020. J Infect Dis. 94:151-3. doi: 10.1016/j.ijid.2020.04.007.

[19]. Clinical Trial Arena. Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19. 2020. Retrieved from https: www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs

[20]. Galal S. Statistics on coronavirus cases in Africa, by country. 2021. https://www.statista.com/statistics/1170463/coronavirus-cases-in-africa/

[21]. Adekunle IA, Onanuga AT, Akinola OO, Ogunbanjo OW. Modelling spatial variations of coronavirus disease (COVID-19) in Nigeria. Geospat Health. 2020;15(1):87-98.

[22]. Elimian KO, Ochu CL, Ilori E, Oladejo J, Igumbor E, Steinhardt L, et al. Descriptive epidemiology of coronavirus disease 2019 in Nigeria, 27 February–6 June 2020. Epidemiol Infect. 2020;148:e208. https://doi.org/10.1017/S095026882000206X

[23]. World Health Organization. Strengthening the health systems response to COVID-19. Geneva: World Health Organization; 2020.

[24]. Johns Hopkins Coronavirus Resource Centre. Mortality analyses. 2020. Retrieved from https://coronavirus.jhu.edu/data/mortality

[25]. World Health Organization Africa. Weekly bulletin on outbreaks and other emergencies: Week 23. 2020. Retrieved from https://apps.who.int/iris/bitstream/handle/10665/332302/OEW23-0107062020.pdf

[26]. Patel SK, Velkoska E, Burrell LM. Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in? Clin Exp Pharmacol Physiol. 2013;40(8):551-9. Doi:10.1111/1440-1681.12069.

[27]. Akanle O, Adesina J, Waobiala UR. Turbulent but I must endure in silence: female breadwinners and survival in southwestern Nigeria. J Asian Afr Stud. 2018;53(1):98-114. Doi:10.1177/0021909616658913.

[28]. Kang L, Ma S, Chen M, Yang J, Wang Y, Li R, et al. Impact on mental health and perceptions of psychological care among medical and nursing staff in Wuhan during the 2019 novel coronavirus disease outbreak: a cross-sectional study. Brain Behav Immun. 2020;87:11-7. https://doi.org/10.1016/j.bbi.2020.03.028

[29]. Chanda-Kapata P, Kapata N, Zumla A. COVID-19 and malaria: a potentially dangerous combination. Int J Infect Dis. 2020;94:151-3. WHO: Malaria factsheet. 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/malaria

[30]. World Health Organization. Malaria factsheet. 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/malaria

[31]. Barranco R, Vallega Bernucci Du Tremoul L, Ventura F. Hospital-acquired SARS-CoV-2 infections in patients: inevitable conditions or medical malpractice? Int J Environ Res Public Health. 2021;18:489.

[32]. Menon V, Padhy SK, Pattnaik JI. Stigma and aggression against health care workers in India amidst COVID-19 times: possible drivers and mitigation strategies. Indian J Psychol Med. 2020;42(4):400-1. Doi:10.1177/0253717620929241.

[33]. Dubey S, Biswas P, Ghosh R, Chatterjee S, Dubey MJ, Chatterjee S, et al. Psychosocial impact of COVID-19. Diabetes Metab Syndr Clin Res Rev. 2020;14(5):779-88. Doi:10.1016/j.dsx.2020.05.035.

[34]. Verma S, Mythily S, Chan YH, Deslypere JP, Teo EK, Chong SA. Post-SARS psychological morbidity and stigma among general practitioners and traditional Chinese medicine practitioners in Singapore. Ann Acad Med Singap. 2004;33(6):743-8.

[35]. Asmundson GJG, Taylor S. Coronaphobia: fear and the 2019-nCoV outbreak [Internet]. J Anxiety Disord. 2020;70. Available from: https://pubmed.ncbi.nlm.nih.gov/32078967/

[36]. In Nigeria, vaccine hesitancy and non-compliance hindering herd immunity-2. 2020.

[37]. Reiter PL, Pennell ML, Katz ML. Acceptability of COVID-19 vaccine among adults in the United States: how many people will get vaccinated? Vaccine. 2020;38(42):6500-7. Doi:10.1016/j.vaccine.2020.08.043.

[38]. Salam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rate. Vaccines (Basel). 2021;9(2):160. Doi:10.3390/vaccines9020160.

[39]. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair allocation of scarce medical resources in the time of COVID-19. N Engl J Med. 2020;382(21):2049-55. Doi:10.1056/NEJMsb2005114.

[40]. Mehrotra A, Chernew M, Linetsky D, Hatch H, Cutler D. What impact has COVID-19 had on outpatient visits? To The Point. 2020.

Viewed	PDF
107	1

Cervical Cancer Screening and Traditional Medicine use among Indigenous Women in Region 1, Guyana

Author: Seraiah Arliana Dimple Validum

DOI: 10.21522/TIJCR.2014.07.01.Art004

[ABSTRACT] [Full-Text PDF] [REFERENCES]

Cervical Cancer Screening and Traditional Medicine use among Indigenous Women in Region 1, Guyana

Abstract:

Cervical cancer disproportionately affects Indigenous women in Guyana's Region 1 (Barima-Waini), a remote, river-dependent area where traditional medicine (TM) is deeply integrated into healthcare decision-making. Drawing on baseline data from 260 Indigenous women across 48 communities enrolled in an ongoing community-based participatory research (CBPR) cohort study, this analysis examined KAP-related proxy indicators regarding cervical cancer screening and TM use, using chi-square tests, Cramer's V effect sizes, and unadjusted pairwise odds ratios (OR) with 95% confidence intervals (CI) to identify factors associated with screening uptake and disclosure behavior (significance set at p < 0.05). Most women (94.2%) were aware of their own Pap smear history, yet lifetime screening uptake was only 32.3%. Screening was most strongly associated with living within 2 km of a health facility (OR = 0.13, 95% CI 0.07–0.25 for those farther away; Cramer's V = 0.421), being 40 years or older (OR = 6.50, 95% CI 3.62–11.69), any use of traditional healers (OR = 3.67, 95% CI 2.08–6.46), and having completed secondary education or higher (OR = 2.57, 95% CI 1.48–4.46). Attitudes followed a non-monotonic pattern: women reporting equal trust in TM and biomedicine were far more likely to combine both approaches (OR = 29.06, 95% CI 13.73–61.49, relative to those favoring biomedicine) and to disclose TM use to a provider (OR = 12.86, 95% CI 6.82–24.24) than women anchored at either extreme of the trust spectrum. While geographic proximity, age, and education remain primary determinants of screening uptake, a balanced trust in both health systems, rather than exclusive alignment with either, shows the strongest unadjusted association with open, integrated care-seeking behavior.

Cervical Cancer Screening and Traditional Medicine use among Indigenous Women in Region 1, Guyana

References:

[1]. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021; 149(4):778-89. Available from: https://doi.org/10.1002/ijc.33588

[2]. Bureau of Statistics Guyana. Population and Housing Census 2012: Final Compendium 2 - Population Composition. Georgetown: Bureau of Statistics Guyana; 2016. Available from: https://statisticsguyana.gov.gy/wp-content/uploads/2019/10/Final_2012_Census_Compendium2.pdf

[3]. Centers for Disease Control and Prevention. Cervical Cancer Screening. Atlanta: CDC; 2023. Available from: https://www.cdc.gov/cervical-cancer/screening/index.html

[4]. Dange S, Aggarwal N, Verma R, Sinha Y, Dadhiya S, Mittal G, Sachdeva R. Computational analysis of Ayurvedic herbs to explore their potential role as anti-cervical cancer agents. Mol Biol Res Commun. 2025; 14(2):129-41. Available from: https://doi.org/10.22099/mbrc.2024.51173.2038

[5]. De Oliveira Lima T, da Silva Junior JE, Vieira Barreto GA, Sátiro Justino MW, Coutinho Carvalho ML, Gurgel Carlos da Silva M, Alves Ferreira D, Gonzaga Silva LF, de Barros Silva PG. Time series and risk factors associated with mortality in women with cervical cancer from 2000 to 2021. Gynecol Oncol Rep. 2024; 55:Art101490. Available from: https://doi.org/10.1016/j.gore.2024.101490

[6]. Houpert R, Sylvestre E, Bouhnik AD, Ben-Diane MK, Najioullah F, Almont T, Boutant W, Macni J, Mancini J, Joachim C, Veronique-Baudin J. Burden of cervical cancer in Martinique, 2012-2021. Cancer Epidemiol. 2025; 97:Art102857. Available from: https://doi.org/10.1016/j.canep.2025.102857

[7]. Bishop A, Sherris J, Tsu VD, Kilbourne-Brook M. Cervical dysplasia treatment: key issues for developing countries. Bull Pan Am Health Organ. 1996;30(4):378-86. Available from: https://pubmed.ncbi.nlm.nih.gov/9041749/

[8]. Ministry of Health, Guyana. Action Plan for the Elimination of Cervical Cancer in Guyana 2024-2030. Georgetown: Ministry of Health; 2024. Available from: https://www.iccp-portal.org/sites/default/files/2026-01/Guyana-Cervical-Cancer-Elimination-Strategy-2024-2030-1.pdf

[9]. Jacob S, Gabriel G, Yap ML, Vinod S, Griffiths K, Sheehan D, Anderson S, Delaney G. Comparison of epidemiology, demography, treatment (surgery and radiotherapy), and survival between Aboriginal and Torres Strait Islander and non-Indigenous women with cervical cancer in NSW, Australia in 2009-2018. Asia Pac J Clin Oncol. 2025; 21(3):266-74. Available from: https://doi.org/10.1111/ajco.14140

[10]. Jeffries A, Beck-Sagué CM, Marroquin-Garcia AB, Dean M, McCoy V, Cordova-Toma DA, Fenkl E, Madhivanan P. Cervical visual inspection with acetic acid (VIA) and oncogenic human papillomavirus screening in rural Indigenous Guatemalan women: time to rethink VIA. Int J Environ Res Public Health. 2021; 18(23):Art12406. Available from: https://doi.org/10.3390/ijerph182312406

[11]. Pan American Health Organization. Cervical Cancer Elimination. Washington (DC): PAHO; 2019. Available from: https://www.paho.org/en/end-cervical-cancer

[12]. International Agency for Research on Cancer. Global Cancer Observatory: GLOBOCAN 2020. Lyon: World Health Organization; 2020. Available from: https://gco.iarc.fr/today

[13]. Gallego-Pérez DF, Mendes Abdala CV, Amado DM, Carvalho de Sousa IM, Aldana-Martínez NS, Ghelman R. Equity, intercultural approaches, and access to information on traditional, complementary, and integrative medicines in the Americas. Rev Panam Salud Publica. 2021; 45:e82. Available from: https://doi.org/10.26633/RPSP.2021.82

[14]. Stormo AR, Altamirano VC, Pérez-Castells M, Espey D, Padilla H, Panameño K, Soria M, Santos C, Saraiya M, Luciani S. Bolivian health providers' attitudes toward alternative technologies for cervical cancer prevention: a focus on visual inspection with acetic acid and cryotherapy. J Womens Health (Larchmt). 2012; 21(8):801-8. Available from: https://doi.org/10.1089/jwh.2012.3796

[15]. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209-49. Available from: https://doi.org/10.3322/caac.21660

[16]. United Nations Development Programme. Human Development Reports. New York: UNDP; 2020. Available from: https://hdr.undp.org

[17]. Wakewich P, Wood B, Davey C, Laframboise A, Zehbe I. Colonial legacy and the experience of First Nations women in cervical cancer screening: a Canadian multi-community study. Crit Public Health. 2016;26(4):368-80. Available from: https://doi.org/10.1080/09581596.2015.1067671

[18]. World Health Organization. Global Health Observatory. Geneva: WHO; 2019. Available from: https://www.who.int/data/gho

[19]. World Health Organization. Cervical Cancer Elimination Initiative. Geneva: WHO; 2020. Available from: https://www.who.int/initiatives/cervical-cancer-elimination-initiative

[20]. World Health Organization. WHO Traditional Medicine Strategy: 2014-2023. Geneva: WHO; 2013. Available from: https://www.who.int/publications/i/item/9789241506096

[21]. World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. Geneva: WHO; 2020. Available from: https://www.who.int/publications/i/item/9789240014107

[22]. World Health Organization. Traditional, Complementary and Integrative Medicine. Geneva: WHO; 2023. Available from: https://www.who.int/health-topics/traditional-complementary-and-integrative-medicine

Viewed	PDF
143	1

Snakebite Clinical Management and Outcomes in the Kingdom of Eswatini - An Analysis of Routine Reports from Public Health Facilities

Author: Nomsa Nompumelelo Dlamini

DOI: 10.21522/TIJCR.2014.07.01.Art005

[ABSTRACT] [Full-Text PDF] [REFERENCES]

Snakebite Clinical Management and Outcomes in the Kingdom of Eswatini - An Analysis of Routine Reports from Public Health Facilities

Abstract:

Snakebite envenoming is a neglected tropical disease that contributes substantially to morbidity, mortality, and disability in sub-Saharan Africa. In Eswatini, snakebites remain a significant public health concern despite recent improvements in surveillance, clinical management, and community awareness. A descriptive correlational secondary data review was conducted using available records of 337 snakebite cases reported at 11 public health facilities in Eswatini between 2020 and 2021. Data was extracted from the Ministry of Health Neglected Tropical Diseases Programme, cleaned, and analyzed using STATA 14/MP. Descriptive statistics summarized patient characteristics, management practices, and treatment outcomes, while logistic regression analyses identified factors associated with antivenom administration, admission, and length of hospitalization. Of the 337 cases, 54% were male and the highest incidence occurred among individuals aged 10–20 years (29%). Most bites occurred while walking on pathways (40.9%) or within household compounds (31.0%), with 66.6% affecting the lower limbs. Cytotoxic envenoming accounted for 59% of cases, while 35% of patients were asymptomatic at presentation. First aid was administered in 71.1% of cases, predominantly through tourniquet use (61.7%). Only 18.5% of patients received antivenom, despite 32.9% presenting clinical syndromes warranting its use. Most patients recovered fully (92.3%), while mortality was 1% (3 patients). Clinically significant envenoming were strongly associated with antivenom administration, hospital admission, and prolonged hospitalization (p < 0.001). Snakebite remains an important public health challenge in Eswatini. Strengthening antivenom availability, healthcare worker capacity, community first-aid education, and surveillance systems is essential to reduce snakebite-related morbidity and mortality and support attainment of the WHO 2030 targets.

Snakebite Clinical Management and Outcomes in the Kingdom of Eswatini - An Analysis of Routine Reports from Public Health Facilities

References:

[1]. Jean-Philippe C, Massougbodji A, Habib AG. The WHO strategy for prevention and control of snakebite envenoming: a sub-Saharan Africa plan. J Venom Anim Toxins Incl Trop Dis. 2019;25.

[2]. Ayesiga I, Mawutor JG, Akaka A, Kubwimana O, Ternor JN, Hashim UM, et al. Health economics of snakebite envenomation: a sub-Saharan African perspective. Trans R Soc Trop Med Hyg. 2025;119:304-9.

[3]. United Nations Population Fund. Eswatini population 2025 [Internet]. 2026 [cited 2026 Aug 11]. Available from: https://www.unfpa.org/data/world-population/SZ

[4]. Ministry of Economic Planning and Development (MEPD). The 2017 population and housing census. Mbabane: Government of the Kingdom of Eswatini; 2017.

[5]. Macrotrends. Eswatini surface area [Internet]. 2026 [cited 2026 Aug 11]. Available from: https://www.macrotrends.net/global-metrics/countries/swz/eswatini/surface-area-km

[6]. Ratanabanangkoon K. Polyvalent snake antivenoms: production strategy and their therapeutic benefits. Toxins (Basel). 2023 Aug 24;15(9):517.

[7]. Williams DJ, Faiz M, Abela-Ridder B, Ainsworth, Bulfone TC, Nickerson AD. Strategy for a globally coordinated response to a priority neglected tropical disease: snakebite envenoming. PLoS Negl Trop Dis. 2019;13:12-14.

[8]. Padidar, Monadjem A, Litschka-Koen, Thomas B, Shongwe, Baker C. Snakebite epidemiology, outcomes and multicluster risk modelling in Eswatini. PLoS Negl Trop Dis. 2023;11.

[9]. Gutiérrez JM, Maduwage K, Iliyasu G, Habib. Snakebite envenoming in different national contexts: Costa Rica, Sri Lanka, and Nigeria. Toxicon X. 2021;9-10.

[10]. Blaylock R. Epidemiology of snakebite in Eshowe, KwaZulu-Natal, South Africa. Toxicon. 2004;159-166.

[11]. Rai A, Chettri M, Dewan S, Khandelwal B, Chettri B. Epidemiological study of snakebite cases in Sikkim: risk modeling with regard to the habitat suitability of common venomous snakes. PLoS Negl Trop Dis. 2021;15:1-24.

[12]. Erickson LT, Litschka-Koen T, Pons J, Bulfone TC, Bhendile G, Fuller S. The “Snake song”: a pilot study of musical intervention in Eswatini. Rural Remote Health. 2020;20.

[13]. Nduwayezu, R, Kinney H, Amuguni JH, Schurer JM. Snakebite envenomation in Rwanda: patient demographics, medical care, and antivenom availability in the formal healthcare sector. Am J Trop Med Hyg. 2021;104:316-322.

[14]. Bertolozzi R, Scatena DC, França DS. Vulnerabilities in snakebites in Sao Paulo, Brazil. 2015;49.

[15]. Ministry of Health. Standard treatment guidelines and essential medicines list of common medical conditions in the Kingdom of Eswatini. Mbabane: Ministry of Health; 2021.

[16]. Yates M, Lebas E, Orpiay R, Bale BJ. Management of snakebites by the staff of a rural clinic: the impact of providing free antivenom in a nurse-led clinic in Meserani, Tanzania. Ann Trop Med Parasitol. 2010;104:439-448.

[17]. Wood D, Webb C, Demeyer J. Severe snakebites in northern KwaZulu-Natal: treatment modalities and outcomes. S Afr Med J. 2009;99:814-818.

[18]. Nuchpraryoon I, Garner P. Interventions for preventing reactions to snake antivenom. Cochrane Database Syst Rev. 2000. 1999.

[19]. Williams DJ, Jensen SD, Nimorakiotakis B, Muller R, Winkel KD. Antivenom use, premedication and early adverse reactions in the management of snake bites in rural Papua New Guinea. Toxicon. 2007;49:780-792.

[20]. Farooq H, Bero C, Guilengue Y, Elias C, Massingue Y, Mucopote I. Snakebite incidence in ruralSnakebite incidence in rural sub-Saharan Africa might be severely underestimated. Toxicon. 2022;219.

[21]. Ooms G, Van Oirschot J, Waldmann B, Okemo D, Mantel-Teeuwisse AK, van den HH. The burden of snakebite in rural communities in Kenya: a household survey. Am J Trop Med Hyg. 2021;828-836.

[22]. Armstrong LJ, Cynthia S, George M, Zachariah A. Comparing community and hospital data of snakebite in North Bihar: a community incidence survey and a parallel hospital-based clinical study. Trop Doct. 2019;49:285-292.

[23]. Harrison RA, Hargreaves A, Wagstaff SC, Faragher B, Lalloo DG. Snake envenoming: a disease of poverty. PLoS Negl Trop Dis. 2009;3.

[24]. Longbottom J, Shearer FM, Devine M, Alcoba G, Chappuis F, Weiss DJ. Vulnerability to snakebite snakebites envenoming: a global mapping of hotspots. Lancet. 2018;392:673-684.

[25]. Shiau DT, Sanders JW, Putnam SD, Buff A, Beasley W, Tribble DR. Self-reported incidence of snake, spider, and scorpion encounters among deployed U.S. military in Iraq and Afghanistan. Mil Med. 2007;172:1099-1102.

[26]. Ochola FO, Okumu MO, Muchemi GM, Mbaria JM, Gikunju JK. Epidemiology of snake bites in selected areas of Kenya. Pan Afr Med J. 2018;29:1-14.

[27]. Gutiérrez JM, Calvete JJ, Habib AG, Harrison RA, Williams DJ, Warrell DA. Snakebite envenoming. Nat Rev Dis Primers. 2017;3.

[28]. Tchoffo D, Kamgno J, Kekeunou S, Yadufashije C, Nana H, Nkwescheu S. High snakebite underreporting rate in the Centre Region of Cameroon: an observational study. BMC Public Health. 2019;19:1-7.

Viewed	PDF
110	1

Table of Contents - Issue

August 2026

Volume 7 | Issue 1

Recent articles

× Texila International Journal

Texila International Journal